Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
US7482149B2 · kind B2 · utility
0Cited by
3References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2004 |
| Grant date | Jan 27, 2009 |
| Priority date | — |
| Expiry date | Aug 4, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN α-n1, IFN α-n3, human leukocyte IFN α or IFN β-1b.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.